OpenAI and the FDA are reportedly discussing AI for drug evaluations

OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to discuss the agency’s use of AI to speed up drug evaluations, Wired reported on Wednesday. According to the report, OpenAI and the FDA have discussed a project called cderGPT, which seems to be an AI tool for the

Check back for our analysis.